Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...

An important clinical trial announcement is good news for this healthcare stock. The post Bell Potter is tipping this exciting ASX healthcare stock to rise 80% appeared first on The Motley Fool ...

Adelaide newsreader Will McDonald has managed his aggressive stage 4 prostate cancer for six years now, although he knows the intensive drug regime he is on, while doing the trick for now, won’t last ...

Researchers looked for incidence of multiple types of cancer in 417,984 Australian women who used medically assisted reproduction from 1991 to 2018.

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Fans were delighted to learn that Sam, one of the show’s most popular characters, was sticking around for a bit longer, hopeful that her stint will crossover with the return of brother Grant (Ross ...

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from ...

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...

Telix Pharmaceuticals reports positive Phase 3 safety results for its investigational prostate cancer therapy, TLX591-Tx. The post Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.

The EAU 2026 CAPTAIN study presentation will be given by Laurence Klotz, CM, MD, FRCSC, an esteemed urologist, a professor of surgery at the University of Toronto, the Sunnybrook Chair of Prostate ...

Testicular cancer is one of the most common cancers affecting young men, especially those between the ages of 20 and 40.